Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Integrated proteogenomic analysis of medulloblastoma progression (DNA methylation)

ABSTRACT: Medulloblastoma is a malignant pediatric brain cancer, whose primary tumors are representatively classified into four molecular subgroups, WNT, SHH, Group 3 and 4. Although the molecular characters have been known well, conventional chemotherapy and radiotherapy after surgery have been used for the treatment to young children, which cause harmful side effects to their chronic health conditions. Moreover, the patients frequently suffer from recurrence and have shown poor prognosis following relapse. Here, we characterized the five layers of molecular profiles and identified potential therapeutic targets of medulloblastoma by performing multi-omics-based analysis including mass spectrometric proteome analysis. The proteome-added integrated analyses characterized new subtypes which showed specific protein functions, such as cell cycle (SHHa), EMT (G4a) and neuronal (G4b and SHHb) functions. Based on the kinase-substrate relations of phospho-proteome, we found the kinase-centered functional modularity of each subtype. These features were significantly associated with clinical features, such as recurrence and progression, and informed us the therapeutic options. Thus, we suggest that our data and analysis would support molecular basis and clinically applicable targets for precision diagnostics and therapeutics of medulloblastoma.

ORGANISM(S): Homo sapiens

PROVIDER: GSE209668 | GEO | 2023/07/31

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Proteogenomic landscape of medulloblastoma subgroups [SNP]

Project description:Extensive high-throughput sequencing led to the characterization of four main medulloblastoma subgroups. However, to date these analyses have not attained a global comprehension of their dynamic network complexity. Wishing to get a comprehensive view of all medulloblastoma subgroups, we employed a proteomic analysis to integrate accurate protein activity. In this study we present the first analysis regrouping genomic and methylation status, whole-transcriptome sequencing and quantitative proteomics. First, our proteomic analysis clarified medulloblastoma subgroup identity. Second, analysis of proteome and phosphoproteome highlighted disregulated signalling pathways that have not been predicted by transcriptomic analysis. Altogether, combined multi-scale analyses of medulloblastoma have allowed us to identify and prioritize novel molecular drivers involved in human medulloblastoma.

2018-09-09 | GSE107508 | GEO

Proteogenomic landscape of medulloblastoma subgroups [methylation]

2018-09-09 | GSE104728 | GEO

The Proteogenomic Landscape of Curable Prostate Cancer [microarray]

Project description:DNA sequencing studies have identified specific recurrent somatic mutations that drive the aggressiveness of localized prostate cancers. Surprisingly, though, it is poorly understood how the prostate cancer proteome is shaped by genomic, epigenomic and transcriptomic dysregulation. To fill this gap, we profiled the whole genomes, methylomes, epigenomes, transcriptomes and proteomes of 55 localized, intermediate-risk, prostate cancers. This multi-modal dataset revealed that the genomic subtypes of prostate cancer converge on four proteomic subtypes, which are associated with distinct clinical trajectories. ETS fusion genes, the most common mutation in prostate tumours, perturb the proteome and transcriptome in divergent ways – with different genes and pathways affected at each level. Indeed, mRNA abundance changes explain only ~10% of variability in protein levels. Perhaps as a direct result, prognostic biomarkers that combine genomic or epigenomic features with proteomic ones significantly outperform those comprised of either molecular feature alone. These data suggest that the proteome of prostate cancer is shaped by a complex interplay of genomic, epigenomic, transcriptomic and post-transcriptional dysregulation.

2019-06-30 | GSE107299 | GEO

Proteogenomic Analysis of Medulloblastoma

Project description:Proteogenomic Analysis of Medulloblastoma

| PRJNA430801 | ENA

Proteogenomic Analysis of Medulloblastoma

Project description:In order to investigate medulloblastoma biology via its proteome, we undertook a super-SILAC quantitative proteomics survey using 41 clinical tissue samples spanning the 4 genomic subgroups and control cerebellum

2018-06-10 | PXD008750 | Pride

Proteogenomic Analysis of Medulloblastoma [methylation array]

Project description:These methylation arrays were performed as part of a project aiming to integrate quantitative proteomic, gene expression and epigenetic data from the childhood brain tumor medulloblastoma.

2018-06-14 | GSE109402 | GEO

Disseminated medulloblastoma in a child with germline BRCA2 6174delT mutation and without Fanconi anemia

Project description:We describe an 8 year old child who had disseminated anaplastic medulloblastoma and a deleterious heterozygous BRCA2 6174delT germline mutation. Molecular profiling was consistent with Group 4 medulloblastoma. The posterior fossa mass was resected and the patient received intensive chemotherapy and craniospinal irradiation. Despite this, the patient succumbed to a second recurrence of his medulloblastoma, which presented eight months after diagnosis as malignant pleural and peritoneal effusions. Continuous medulloblastoma cell lines were isolated from the original tumor (CHLA-01-MED) and the malignant pleural effusion (CHLA-01R-MED). Here we provide their analyses, including in vitro and in vivo growth, drug sensitivity, comparative genomic hybridization and next generation sequencing analysis. In addition to the BRCA2 6174delT, the medulloblastoma cells had amplification of MYC, deletion at Xp11.2 and isochromosome 17, but no structural variations or overexpression of GFI1 or GFI1B. To our knowledge, this is the first pair of diagnosis/recurrence medulloblastoma cell lines, the only medulloblastoma cell lines with BRCA2 6174delT described to date, and the first reported case of a child with medulloblastoma associated with a germline BRCA2 6174delT who did not also have Fanconi anemia. Continuous medulloblastoma cell lines were isolated from the original tumor (CHLA-01-MED) and the malignant pleural effusion (CHLA-01R-MED). Here we provide their analyses, including in vitro and in vivo growth, drug sensitivity, comparative genomic hybridization with Agilent 400k CGH arrays and whole transcriptome RNASeq analysis.

2015-07-06 | E-GEOD-70003 | biostudies-arrayexpress

Proteogenomic Analysis of Medulloblastoma [gene expression microarray]

Project description:These gene expression microarrays were performed as part of a project aiming to integrate quantitative proteomic, gene expression and epigenetic data from the childhood brain tumor medulloblastoma.

2018-06-14 | GSE109401 | GEO

mRNA expression data of 62 human medulloblastoma tumors

Project description:To identify molecular subtypes of medulloblastoma we have profiled a series of 62 medulloblastoma tumors. Unsupervised hierarchical cluster analysis of these data identified 5 distinct molecular subtypes. Manuscript submitted. Title: Identification of medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. Authors: Marcel Kool, Jan Koster, Jens Bunt, Nancy E. Hasselt, Arjan Lakeman, Peter van Sluis, Dirk Troost, Netteke Schouten â van Meeteren, Huib N. Caron, Alan MrÅ¡iÄ, Bauke Ylstra, Wieslawa Grajkowska, Wolfgang Hartmann, Torsten Pietsch, David Ellison, Steven C. Clifford, Rogier Versteeg. Keywords: tumor classification 62 human medulloblastoma samples were analzyed

2008-09-02 | E-GEOD-10327 | biostudies-arrayexpress

Proteogenomic landscape of medulloblastoma subgroups

Project description:Proteogenomic landscape of medulloblastoma subgroups

| PRJNA420382 | ENA